Adam S Garden

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1401799/publications.pdf

Version: 2024-02-01

373	27,343	5248	7718
papers	citations	83 h-index	150 g-index

381	381	381	17653
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. International Journal of Radiation Oncology Biology Physics, 2000, 48, 7-16.	0.4	1,222
2	Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis. Journal of Clinical Oncology, 2008, 26, 3582-3589.	0.8	1,188
3	Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522. Journal of Clinical Oncology, 2014, 32, 2940-2950.	0.8	697
4	Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. International Journal of Radiation Oncology Biology Physics, 2004, 59, 960-970.	0.4	643
5	Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225. Journal of Clinical Oncology, 2009, 27, 3684-3690.	0.8	607
6	Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncology, The, 2016, 17, 440-451.	5.1	607
7	Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2001, 51, 571-578.	0.4	566
8	Validation of an accelerated â€˜demonsâ€™ algorithm for deformable image registration in radiation therapy. Physics in Medicine and Biology, 2005, 50, 2887-2905.	1.6	537
9	Evaluation of the dose for postoperative radiation therapy of head and neck cancer: First report of a prospective randomized trial. International Journal of Radiation Oncology Biology Physics, 1993, 26, 3-11.	0.4	479
10	Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma. Journal of Clinical Oncology, 2014, 32, 3365-3373.	0.8	449
11	Risk, Outcomes, and Costs of Radiation-Induced Oral Mucositis Among Patients With Head-and-Neck Malignancies. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1110-1120.	0.4	405
12	The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. International Journal of Radiation Oncology Biology Physics, 1995, 32, 619-626.	0.4	401
13	Multi-Institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early-Stage Oropharyngeal Cancer (RTOG 00-22). International Journal of Radiation Oncology Biology Physics, 2010, 76, 1333-1338.	0.4	336
14	Patientâ€reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. Cancer, 2008, 113, 2704-2713.	2.0	310
15	Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncology, The, 2012, 13, 172-180.	5.1	291
16	Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of local and regional control. International Journal of Radiation Oncology Biology Physics, 1997, 37, 985-996.	0.4	265
17	Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial. Journal of Clinical Oncology, 2010, 28, 8-14.	0.8	234
18	Parathyroid carcinoma: A 22-year experience. Head and Neck, 2004, 26, 716-726.	0.9	233

#	Article	IF	Citations
19	Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module. Head and Neck, 2007, 29, 923-931.	0.9	227
20	IMRT Reirradiation of Head and Neck Cancerâ€"Disease Control and Morbidity Outcomes. International Journal of Radiation Oncology Biology Physics, 2009, 73, 399-409.	0.4	218
21	Radiation-induced Xerostomia in patients with head and neck cancer: Pathogenesis, impact on quality of life, and management. Head and Neck, 2004, 26, 796-807.	0.9	213
22	Osteoradionecrosis and Radiation Dose to the Mandible in Patients With Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 415-420.	0.4	209
23	Cerebrovascular Disease Risk in Older Head and Neck Cancer Patients After Radiotherapy. Journal of Clinical Oncology, 2008, 26, 5119-5125.	0.8	206
24	Adaptive Radiotherapy for Head-and-Neck Cancer: Initial Clinical Outcomes From a Prospective Trial. International Journal of Radiation Oncology Biology Physics, 2012, 83, 986-993.	0.4	205
25	Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. International Journal of Radiation Oncology Biology Physics, 1995, 33, 179-182.	0.4	199
26	Final Results of Local-Regional Control and Late Toxicity of RTOG 9003: A Randomized Trial of Altered Fractionation Radiation for Locally Advanced Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 89, 13-20.	0.4	198
27	Postoperative radiotherapy for cutaneous melanoma of the head and neck region. International Journal of Radiation Oncology Biology Physics, 1994, 30, 795-798.	0.4	194
28	TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncology, The, 2007, 8, 613-624.	5.1	191
29	Adult rhabdomyosarcoma. Cancer, 2002, 95, 377-388.	2.0	189
30	Sinonasal malignancies with neuroendocrine differentiation. Cancer, 2004, 101, 2567-2573.	2.0	187
31	Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma. Cancer, 1995, 76, 319-327.	2.0	185
32	Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma. JAMA Oncology, 2016, 2, 782.	3.4	185
33	Preliminary Results of Radiation Therapy Oncology Group 97-03: A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck. Journal of Clinical Oncology, 2004, 22, 2856-2864.	0.8	177
34	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer â€" A case matched analysis. Radiotherapy and Oncology, 2016, 120, 48-55.	0.3	177
35	Postoperative radiotherapy for malignant tumors of the parotid gland. International Journal of Radiation Oncology Biology Physics, 1997, 37, 79-85.	0.4	176
36	Postoperative radiation therapy for malignant tumors of minor salivary glands. Outcome and patterns of failure. Cancer, 1994, 73, 2563-2569.	2.0	172

#	Article	IF	Citations
37	Beam Path Toxicities to Non-Target Structures During Intensity-Modulated Radiation Therapy for Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 747-755.	0.4	168
38	Adaptive radiotherapy for head and neck cancerâ€"Dosimetric results from a prospective clinical trial. Radiotherapy and Oncology, 2013, 106, 80-84.	0.3	168
39	Multiple regions-of-interest analysis of setup uncertainties for head-and-neck cancer radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1559-1569.	0.4	165
40	Prognostic factors in mucoepidermoid carcinoma of the salivary glands. Cancer, 2012, 118, 3928-3936.	2.0	165
41	Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. Radiotherapy and Oncology, 1997, 43, 53-61.	0.3	159
42	Prospective Risk-Adjusted [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Assessment of Radiation Response in Head and Neck Cancer. Journal of Clinical Oncology, 2009, 27, 2509-2515.	0.8	156
43	Candidate Dosimetric Predictors of Long-Term Swallowing Dysfunction After Oropharyngeal Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1356-1365.	0.4	156
44	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 618-627.	0.4	156
45	Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: Radiation Therapy Oncology Group Phase II Trial 99-14. Journal of Clinical Oncology, 2005, 23, 3008-3015.	0.8	151
46	An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center. Cancer, 2013, 119, 81-89.	2.0	145
47	Postoperative External Beam Radiotherapy for Differentiated Thyroid Cancer: Outcomes and Morbidity With Conformal Treatment. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1083-1091.	0.4	143
48	Neck surgery in patients with primary oropharyngeal cancer treated by radiotherapy. , 1996, 18, 552-559.		134
49	Results of radiotherapy for T2N0 glottic carcinoma: does the â€œ2â€•stand for twice-daily treatment?. International Journal of Radiation Oncology Biology Physics, 2003, 55, 322-328.	0.4	130
50	Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 67, 438-444.	0.4	130
51	Parotid Gland Dose in Intensity-Modulated Radiotherapy for Head and Neck Cancer: Is What You Plan What You Get?. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1290-1296.	0.4	130
52	Improved survival using intensityâ€•modulated radiation therapy in head and neck cancers: A SEERâ€•Medicare analysis. Cancer, 2014, 120, 702-710.	2.0	129
53	Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiotherapy and Oncology, 1991, 20, 99-110.	0.3	128
54	Multifield Optimization Intensity Modulated Proton Therapy for Head and Neck Tumors: A Translation to Practice. International Journal of Radiation Oncology Biology Physics, 2014, 89, 846-853.	0.4	128

#	Article	IF	Citations
55	Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. International Journal of Radiation Oncology Biology Physics, 2016, 96, 30-41.	0.4	123
56	Postoperative radiation for squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: Outcomes and patterns of failure. , 1998, 20, 674-681.		122
57	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1107-1114.	0.4	121
58	A multinational, randomized phase iii trial of iseganan hcl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology Biology Physics, 2004, 58, 674-681.	0.4	119
59	Minor salivary gland tumors of the palate: Clinical and pathologic correlates of outcome. Laryngoscope, 1995, 105, 1155-1160.	1.1	116
60	Combined Interferon-Alfa, 13-cis-Retinoic Acid, and Alpha-Tocopherol in Locally Advanced Head and Neck Squamous Cell Carcinoma: Novel Bioadjuvant Phase II Trial. Journal of Clinical Oncology, 2001, 19, 3010-3017.	0.8	115
61	Prognosis and risk factors for earlyâ€stage adenoid cystic carcinoma of the major salivary glands. Cancer, 2012, 118, 2872-2878.	2.0	115
62	Comparison of 2D Radiographic Images and 3D Cone Beam Computed Tomography for Positioning Head-and-Neck Radiotherapy Patients. International Journal of Radiation Oncology Biology Physics, 2008, 71, 916-925.	0.4	112
63	Mucositis-Related Morbidity and Resource Utilization in Head and Neck Cancer Patients Receiving Radiation Therapy With or Without Chemotherapy. Journal of Pain and Symptom Management, 2009, 38, 522-532.	0.6	112
64	Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid, 2018, 28, 945-951.	2.4	111
65	Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer, 2003, 97, 1789-1796.	2.0	110
66	A multiâ€institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensityâ€modulated radiotherapy. Cancer, 2015, 121, 294-301.	2.0	109
67	Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: A prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventoryâ€Head and Neck Module. Cancer, 2014, 120, 1975-1984.	2.0	106
68	Intensity modulated proton therapy (IMPT) â€“ The future of IMRT for head and neck cancer. Oral Oncology, 2019, 88, 66-74.	0.8	103
69	Intensityâ€modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes. Head and Neck, 2016, 38, E1886-95.	0.9	102
70	Long-Term Results of Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: A Phase II Trial of the Radiation Therapy Oncology Group (RTOG 99-14). International Journal of Radiation Oncology Biology Physics, 2008, 71, 1351-1355.	0.4	101
71	Adherence to preventive exercises and selfâ€reported swallowing outcomes in postâ€radiation head and neck cancer patients. Head and Neck, 2013, 35, 1707-1712.	0.9	101
72	Longâ€term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3â€decade survey. Cancer, 2015, 121, 1608-1619.	2.0	100

#	Article	IF	Citations
73	Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1117-1131.	0.4	100
74	Patterns of Disease Recurrence Following Treatment of Oropharyngeal Cancer With Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 941-947.	0.4	99
75	Performance Evaluation of Automatic Anatomy Segmentation Algorithm on Repeat or Four-Dimensional Computed Tomography Images Using Deformable Image Registration Method. International Journal of Radiation Oncology Biology Physics, 2008, 72, 210-219.	0.4	98
76	Phase III Trial of an Emulsion Containing Trolamine for the Prevention of Radiation Dermatitis in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Trial 99-13. Journal of Clinical Oncology, 2006, 24, 2092-2097.	0.8	97
77	Prospective randomized double-blind study of atlas-based organ-at-risk autosegmentation-assisted radiation planning in head and neck cancer. Radiotherapy and Oncology, 2014, 112, 321-325.	0.3	96
78	Unilateral Radiotherapy for the Treatment of Tonsil Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 204-209.	0.4	94
79	Simple Carotid-Sparing Intensity-Modulated Radiotherapy Technique and Preliminary Experience for T1â€“2 Glottic Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 455-461.	0.4	89
80	Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiation Oncology, 2013, 8, 21.	1.2	89
81	Superior sulcus tumors: Treatment selection and results for 85 patients without metastasis (Mo) at presentation. International Journal of Radiation Oncology Biology Physics, 1990, 19, 31-36.	0.4	88
82	Spot-scanning beam proton therapy vs intensity-modulated radiation therapy for ipsilateral head and neck malignancies: A treatment planning comparison. Medical Dosimetry, 2013, 38, 390-394.	0.4	88
83	Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 95, 360-367.	0.4	88
84	Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?. Cancer, 2004, 100, 1171-1178.	2.0	87
85	Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer, 2007, 109, 1914-1922.	2.0	86
86	Postoperative Radiotherapy for Maxillary Sinus Cancer: Long-Term Outcomes and Toxicities of Treatment. International Journal of Radiation Oncology Biology Physics, 2007, 68, 719-730.	0.4	86
87	Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and NeckÂCancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1002-1011.	0.4	86
88	Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Doseâ€“volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. Radiotherapy and Oncology, 2016, 118, 304-314.	0.3	85
89	Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes. International Journal of Radiation Oncology Biology Physics, 2006, 64, 678-683.	0.4	83
90	DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy. Clinical Cancer Research, 2011, 17, 2035-2043.	3.2	81

#	Article	IF	Citations
91	Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head and Neck, 2010, 32, 829-836.	0.9	80
92	Clinical Practice Guidance for Radiotherapy Planning After Induction Chemotherapy in Locoregionally Advanced Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 725-733.	0.4	80
93	Postoperative radiotherapy for advanced medullary thyroid cancerâ€"Local disease control in the modern era. Head and Neck, 2008, 30, 883-888.	0.9	78
94	Complications of radiotherapy in laryngopharyngeal cancer. Cancer, 2009, 115, 4636-4644.	2.0	78
95	Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. Radiotherapy and Oncology, 2016, 121, 381-386.	0.3	78
96	Management of nonsinonasal neuroendocrine carcinomas of the head and neck. Cancer, 2003, 98, 2322-2328.	2.0	77
97	Intensity-modulated radiation therapy (IMRT) of cancers of the head and neck: Comparison of split-field and whole-field techniques. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1000-1005.	0.4	76
98	Proton Therapy Reduces Treatment-Related Toxicities for Patients with Nasopharyngeal Cancer: A Case-Match Control Study of Intensity-Modulated Proton Therapy and Intensity-Modulated Photon Therapy. International Journal of Particle Therapy, 2015, 2, 19-28.	0.9	76
99	Intensity-Modulated Radiotherapy for Cervical Node Squamous Cell Carcinoma Metastases From Unknown Head-and-Neck Primary Site: M. D. Anderson Cancer Center Outcomes and Patterns of Failure. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1005-1010.	0.4	75
100	Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: The M. D. Anderson cancer center experience. Head and Neck, 1994, 16, 39-44.	0.9	74
101	Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. Radiotherapy and Oncology, 2017, 123, 401-405.	0.3	73
102	The M. D. Anderson Symptom Inventoryâ€"Head and Neck Module, a Patient-Reported Outcome Instrument, Accurately Predicts the Severity of Radiation-Induced Mucositis. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1355-1361.	0.4	72
103	Automatic detection of contouring errors using convolutional neural networks. Medical Physics, 2019, 46, 5086-5097.	1.6	72
104	Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer, 2004, 100, 383-389.	2.0	71
105	Importance of patient examination to clinical quality assurance in head and neck radiation oncology. Head and Neck, 2006, 28, 967-973.	0.9	70
106	Base-of-tongue carcinoma: Treatment results using concomitant boost radiotherapy. International Journal of Radiation Oncology Biology Physics, 1995, 33, 289-296.	0.4	69
107	Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. Radiotherapy and Oncology, 2017, 124, 232-239.	0.3	69
108	Postoperative radiotherapy for malignant tumors of the submandibular gland. International Journal of Radiation Oncology Biology Physics, 2001, 51, 952-958.	0.4	68

#	Article	IF	Citations
109	Radiation Therapy for Nonmelanoma Skin Carcinomas. Clinics in Plastic Surgery, 1997, 24, 719-729.	0.7	65
110	Ethmoid sinus carcinomas: natural history and treatment results. Radiotherapy and Oncology, 1998, 49, 21-27.	0.3	65
111	Primary carcinoma of the female urethra results of radiation therapy. Cancer, 1993, 71, 3102-3108.	2.0	64
112	Early squamous cell carcinoma of the hypopharynx: Outcomes of treatment with radiation alone to the primary disease. , 1996, 18, 317-322.		64
113	Metabolic Tumor Volume as a Prognostic Imaging-Based Biomarker for Head-and-Neck Cancer: Pilot Results From Radiation Therapy Oncology Group Protocol 0522. International Journal of Radiation Oncology Biology Physics, 2015, 91, 721-729.	0.4	64
114	Proposed Staging System for Patients With HPV-Related Oropharyngeal Cancer Based on Nasopharyngeal Cancer N Categories. Journal of Clinical Oncology, 2016, 34, 1848-1854.	0.8	64
115	Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. Clinical Cancer Research, 2020, 26, 3211-3219.	3.2	64
116	Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Seminars in Radiation Oncology, 2004, 14, 103-109.	1.0	62
117	Radiation therapy for early-stage carcinoma of the oropharynx. International Journal of Radiation Oncology Biology Physics, 2004, 59, 743-751.	0.4	62
118	Outcomes of malignant tumors of the lacrimal apparatus. Cancer, 2011, 117, 2801-2810.	2.0	62
119	Prediction of Neck Dissection Requirement After Definitive Radiotherapy for Head-and-Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2012, 82, e367-e374.	0.4	62
120	Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer, 2016, 122, 534-545.	2.0	62
121	Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. Medical Dosimetry, 2016, 41, 189-194.	0.4	62
122	Can positron emission tomography improve the quality of care for head-and-neck cancer patients?. International Journal of Radiation Oncology Biology Physics, 2001, 51, 4-9.	0.4	61
123	Pretreatment Quality of Life Predicts for Locoregional Control in Head and Neck Cancer Patients: A Radiation Therapy Oncology Group Analysis. International Journal of Radiation Oncology Biology Physics, 2008, 70, 353-360.	0.4	61
124	Hypopharyngeal Dose Is Associated With Severe Late Toxicity in Locally Advanced Head-and-Neck Cancer: An RTOG Analysis. International Journal of Radiation Oncology Biology Physics, 2012, 84, 983-989.	0.4	61
125	Selective vs Modified Radical Neck Dissection and Postoperative Radiotherapy vs Observation in the Treatment of Squamous Cell Carcinoma of the Oral Tongue. JAMA Otolaryngology, 2005, 131, 874.	1.5	60
126	Phase I/II Study of Docetaxel, Cisplatin, and Concomitant Boost Radiation for Locally Advanced Squamous Cell Cancer of the Head and Neck. Journal of Clinical Oncology, 2006, 24, 4163-4169.	0.8	59

#	Article	IF	Citations
127	Disadvantage of Men Living Alone Participating in Radiation Therapy Oncology Group Head and Neck Trials. Journal of Clinical Oncology, 2006, 24, 4177-4183.	0.8	59
128	Quality Assurance Assessment of Diagnostic and Radiation Therapyâ€“Simulation CT Image Registration for Head and Neck Radiation Therapy: Anatomic Region of Interestâ€“based Comparison of Rigid and Deformable Algorithms. Radiology, 2015, 274, 752-763.	3.6	58
129	Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma. , 1997, 79, 1279-1286.		56
130	Electron conformal radiotherapy using bolus and intensity modulation. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1023-1037.	0.4	56
131	Risk of osteoradionecrosis after extraction of impacted third molars in irradiated head and neck cancer patients. Journal of Oral and Maxillofacial Surgery, 2004, 62, 139-144.	0.5	56
132	Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. Cancer, 2008, 112, 111-118.	2.0	56
133	Long-Term Radiotherapy Outcomes for Nasal Cavity and Septal Cancers. International Journal of Radiation Oncology Biology Physics, 2008, 71, 401-406.	0.4	55
134	Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. Cancer, 2017, 123, 1653-1661.	2.0	55
135	Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer, 2002, 95, 322-330.	2.0	54
136	Beam path toxicity in candidate organs-at-risk: Assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. Radiotherapy and Oncology, 2014, 111, 281-288.	0.3	54
137	Prospective Qualitative and Quantitative Analysis of Real-Time Peer Review Quality Assurance Rounds Incorporating Direct Physical Examination for Head and Neck Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 532-540.	0.4	54
138	Radiation Therapy for Early Stage (T1-T2) Sarcomatoid Carcinoma of True Vocal Cords: Outcomes and Patterns of Failure. Laryngoscope, 1998, 108, 760-763.	1.1	53
139	Phase I/II Trial of Radiation With Chemotherapy â€œBoostâ€•for Advanced Squamous Cell Carcinomas of the Head and Neck: Toxicities and Responses. Journal of Clinical Oncology, 1999, 17, 2390-2390.	0.8	53
140	Head and neck carcinoma in the United States. Cancer, 2012, 118, 5783-5792.	2.0	53
141	Evaluating the impact of patient, tumor, and treatment characteristics on the development of jaw complications in patients treated for oral cancers: A SEER-Medicare analysis. Head and Neck, 2013, 35, 1599-1605.	0.9	52
142	Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: A comparison of two fractionation schedules. International Journal of Radiation Oncology Biology Physics, 1995, 31, 493-502.	0.4	51
143	Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study. NMR in Biomedicine, 2015, 28, 1645-1654.	1.6	51
144	Auto-delineation of oropharyngeal clinical target volumes using 3D convolutional neural networks. Physics in Medicine and Biology, 2018, 63, 215026.	1.6	51

#	Article	IF	Citations
145	Dysphagia After Primary Transoral Robotic Surgery With Neck Dissection vs Nonsurgical Therapy in Patients With Low- to Intermediate-Risk Oropharyngeal Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 1053.	1.2	51
146	Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Scientific Data, 2018, 5, 180173.	2.4	51
147	The role of interstitial brachytherapy with salvage surgery for the management of recurrent head and neck cancers. Cancer, 2007, 109, 2052-2057.	2.0	49
148	The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. Cancer, 2013, 119, 3162-3169.	2.0	49
149	A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa. International Journal of Radiation Oncology Biology Physics, 2016, 95, 344-352.	0.4	49
150	Generating High-Quality Lymph Node Clinical Target Volumes for Head and Neck Cancer Radiation Therapy Using a Fully Automated Deep Learning-Based Approach. International Journal of Radiation Oncology Biology Physics, 2021, 109, 801-812.	0.4	49
151	Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer, 2003, 98, 2214-2223.	2.0	48
152	Concomitant boost radiotherapy for squamous carcinoma of the tonsillar fossa. International Journal of Radiation Oncology Biology Physics, 1997, 39, 127-135.	0.4	47
153	New thoughts on the pathobiology of regimen-related mucosal injury. Supportive Care in Cancer, 2006, 14, 516-518.	1.0	47
154	Durable Long-Term Remission With Chemotherapy Alone for Stage II to IV Laryngeal Cancer. Journal of Clinical Oncology, 2009, 27, 1976-1982.	0.8	47
155	The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. International Journal of Radiation Oncology Biology Physics, 2019, 104, 724-733.	0.4	47
156	Long-Term, Prospective Performance of the MDÂAnderson Dysphagia Inventory in â€œLow-Intermediate Riskâ€•Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 97, 700-708.	0.4	46
157	Postoperative Adjuvant External-Beam Radiation Therapy for Cancers of the Eyelid and Conjunctiva. Ophthalmic Plastic and Reconstructive Surgery, 2008, 24, 444-449.	0.4	45
158	Prognostic Factors Associated With Decreased Survival in Patients With Acinic Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2013, 139, 1195.	1.2	45
159	Open-Label, Long-Term Safety Study of Cevimeline in the Treatment of Postirradiation Xerostomia. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1369-1376.	0.4	44
160	Gastrostomy in oropharyngeal cancer patients with ERCC4 (XPF) germline variants. International Journal of Radiation Oncology Biology Physics, 2005, 62, 665-671.	0.4	43
161	Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck. Cancer, 2008, 112, 2698-2709.	2.0	43
162	Longâ€term functional and survival outcomes after induction chemotherapy and riskâ€based definitive therapy for locally advanced squamous cell carcinoma of the head and neck. Head and Neck, 2014, 36, 474-480.	0.9	43

#	Article	IF	Citations
163	A multimodality segmentation framework for automatic target delineation in head and neck radiotherapy. Medical Physics, 2015, 42, 5310-5320.	1.6	43
164	Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease?. Head and Neck, 2005, 27, 718-721.	0.9	42
165	Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. Cancer, 2021, 127, 1788-1795.	2.0	42
166	Controversies in Surgical Management of the Node-Positive Neck After Chemoradiation. Seminars in Radiation Oncology, 2009, 19, 24-28.	1.0	41
167	Longitudinal oncology registry of head and neck carcinoma (LORHAN). Cancer, 2011, 117, 1679-1686.	2.0	41
168	Identifying Early Dehydration Risk With Home-Based Sensors During Radiation Treatment: A Feasibility Study on Patients With Head and Neck Cancer. Journal of the National Cancer Institute Monographs, 2013, 2013, 162-168.	0.9	41
169	The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Practical Radiation Oncology, 2016, 6, 241-247.	1.1	41
170	Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clinical and Translational Radiation Oncology, 2018, 13, 19-23.	0.9	41
171	Comparison between normal tissue reactions and local tumor control in head and neck cancer patients treated by definitive radiotherapy. International Journal of Radiation Oncology Biology Physics, 1996, 35, 455-462.	0.4	40
172	Early Postoperative Paclitaxel Followed by Concurrent Paclitaxel and Cisplatin With Radiation Therapy for Patients With Resected High-Risk Head and Neck Squamous Cell Carcinoma: Report of the Phase II Trial RTOG 0024. Journal of Clinical Oncology, 2009, 27, 4727-4732.	0.8	40
173	A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma. Practical Radiation Oncology, 2015, 5, e169-e176.	1.1	40
174	Carcinomas of the nasal cavity. Radiotherapy and Oncology, 1992, 24, 163-168.	0.3	39
175	Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes. Radiation Oncology, 2014, 9, 255.	1.2	39
176	Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography. International Journal of Radiation Oncology Biology Physics, 1996, 36, 1005-1012.	0.4	38
177	Olfactory Neuroblastoma and Neuroendocrine Carcinoma of the Anterior Skull Base: Treatment Results at the M.D. Anderson Cancer Center. Skull Base, 1996, 6, 1-8.	0.4	37
178	Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma. Laryngoscope, 2017, 127, 842-848.	1.1	37
179	A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer, 2004, 100, 991-998.	2.0	36
180	Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. International Journal of Clinical Oncology, 2007, 12, 99-110.	1.0	36

#	Article	IF	Citations
181	Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: A series of 9 cases and a critical review of the literature. Head and Neck, 2016, 38, E1472-80.	0.9	36
182	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. International Journal of Radiation Oncology Biology Physics, 2017, 97, 687-699.	0.4	35
183	Assessment of shoulder position variation and its impact on IMRT and VMAT doses for head and neck cancer. Radiation Oncology, 2012, 7, 19.	1.2	34
184	Methodology for analysis and reporting patterns of failure in the Era of IMRT: head and neck cancer applications. Radiation Oncology, 2016, 11, 95.	1.2	34
185	Intensity-modulated radiotherapy: Is xerostomia still prevalent?. Current Oncology Reports, 2005, 7, 131-136.	1.8	33
186	The Effect of Dental Artifacts, Contrast Media, and Experience on Interobserver Contouring Variations in Head and Neck Anatomy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 191-198.	0.6	33
187	Longâ€term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. Head and Neck, 2016, 38, 1739-1751.	0.9	33
188	Merkel cell carcinoma of the head and neck: Favorable outcomes with radiotherapy. Head and Neck, 2016, 38, E452-8.	0.9	32
189	Improved setup and positioning accuracy using a threeâ€point customized cushion/mask/biteâ€block immobilization system for stereotactic reirradiation of head and neck cancer. Journal of Applied Clinical Medical Physics, 2016, 17, 180-189.	0.8	32
190	Delayed lower cranial neuropathy after oropharyngeal intensityâ€modulated radiotherapy: A cohort analysis and literature review. Head and Neck, 2017, 39, 1516-1523.	0.9	32
191	Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions. Radiotherapy and Oncology, 2017, 124, 248-255.	0.3	32
192	Design and fabrication of a 3Dâ€“printed oral stent for head and neck radiotherapy from routine diagnostic imaging. 3D Printing in Medicine, 2017, 3, 12.	1.7	31
193	Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. Npj Precision Oncology, 2019, 3, 22.	2.3	31
194	Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma. BMC Cancer, 2020, 20, 912.	1.1	31
195	Hypothyroidism in older patients with head and neck cancer after treatment with radiation: A populationâ€based study. Head and Neck, 2009, 31, 1031-1038.	0.9	30
196	Creating customized oral stents for head and neck radiotherapy using 3D scanning and printing. Radiation Oncology, 2019, 14, 148.	1.2	30
197	Impact of Gender, Partner Status, and Race on Locoregional Failure and Overall Survival in Head and Neck Cancer Patients in Three Radiation Therapy Oncology Group Trials. International Journal of Radiation Oncology Biology Physics, 2011, 81, e101-e109.	0.4	29
198	Depression and Oropharynx Cancer Outcome. Psychosomatic Medicine, 2016, 78, 38-48.	1.3	29

#	Article	IF	Citations
199	Quantitative body mass characterization before and after head and neck cancer radiotherapy: A challenge of height-weight formulae using computed tomography measurement. Oral Oncology, 2016, 61, 62-69.	0.8	29
200	Development and validation of a 3Dâ€printed bolus cap for total scalp irradiation. Journal of Applied Clinical Medical Physics, 2019, 20, 89-96.	0.8	29
201	Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head and Neck, 2020, 42, 1939-1953.	0.9	29
202	Auto-segmentation of low-risk clinical target volume for head and neck radiation therapy. Practical Radiation Oncology, 2014, 4, e31-e37.	1.1	28
203	Prognostic value of p16 expression in Epsteinâ€Barr virusâ€“positive nasopharyngeal carcinomas. Head and Neck, 2016, 38, E1459-66.	0.9	28
204	Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: TheÂRTOG Experience. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1346-1354.	0.4	28
205	Atlas ranking and selection for automatic segmentation of the esophagus from CT scans. Physics in Medicine and Biology, 2017, 62, 9140-9158.	1.6	28
206	Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer, 2019, 125, 1823-1829.	2.0	28
207	Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. Oral Oncology, 2017, 72, 90-97.	0.8	28
208	Management of the lymph nodeâ€positive neck in the patient with human papillomavirusâ€associated oropharyngeal cancer. Cancer, 2014, 120, 3082-3088.	2.0	27
209	Prospective in silico study of the feasibility and dosimetric advantages of MRI-guided dose adaptation for human papillomavirus positive oropharyngeal cancer patients compared with standard IMRT. Clinical and Translational Radiation Oncology, 2018, 11, 11-18.	0.9	27
210	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. Seminars in Radiation Oncology, 2018, 28, 108-113.	1.0	26
211	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients â‰¥65Âyears old. Radiation Oncology, 2017, 12, 150.	1.2	25
212	Patient-reported outcomes of symptom burden in patients receiving surgical or nonsurgical treatment for low-intermediate risk oropharyngeal squamous cell carcinoma: A comparative analysis of a prospective registry. Oral Oncology, 2019, 91, 13-20.	0.8	25
213	Outcomes of carotidâ€sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. Laryngoscope, 2020, 130, 146-153.	1.1	25
214	Reduced feeding tube duration with intensityâ€modulated radiation therapy for head and neck cancer: A Surveillance, Epidemiology, and End Resultsâ€Medicare Analysis. Cancer, 2017, 123, 283-293.	2.0	24
215	Chronic radiation-associated dysphagia in oropharyngeal cancer survivors: Towards age-adjusted dose constraints for deglutitive muscles. Clinical and Translational Radiation Oncology, 2019, 18, 16-22.	0.9	24
216	Prospective quantitative quality assurance and deformation estimation of MRI-CT image registration in simulation of head and neck radiotherapy patients. Clinical and Translational Radiation Oncology, 2019, 18, 120-127.	0.9	24

#	Article	IF	Citations
217	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. Radiotherapy and Oncology, 2020, 151, 314-321.	0.3	24
218	A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics, 2005, 63, 717-724.	0.4	23
219	Radiation-associated head and neck sarcomas: Spectrum of imaging findings. Oral Oncology, 2012, 48, 155-161.	0.8	23
220	Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma. Practical Radiation Oncology, 2014, 4, e189-e194.	1.1	22
221	Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensityâ€modulated radiotherapy. Head and Neck, 2016, 38, E925-33.	0.9	22
222	Prospective Imaging Assessment of Mortality Risk After Head-and-Neck Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 667-674.	0.4	21
223	Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. Radiotherapy and Oncology, 2015, 117, 132-138.	0.3	21
224	Magnetic resonance imaging of swallowing-related structures in nasopharyngeal carcinoma patients receiving IMRT: Longitudinal doseâ€“response characterization of quantitative signal kinetics. Radiotherapy and Oncology, 2016, 118, 315-322.	0.3	21
225	Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. Radiotherapy and Oncology, 2020, 142, 133-139.	0.3	21
226	Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. Radiotherapy and Oncology, 2020, 148, 258-266.	0.3	21
227	How to reduce radiation-related toxicity in patients with cancer of the head and neck. Current Oncology Reports, 2006, 8, 140-145.	1.8	20
228	Medical Physics, 2012, 39, 5136-5144.	1.6	20
229	Prospective assessment of an atlas-based intervention combined with real-time software feedback in contouring lymph node levels and organs-at-risk in the head and neck: Quantitative assessment of conformance to expert delineation. Practical Radiation Oncology, 2013, 3, 186-193.	1.1	20
230	Ageâ€adjusted comorbidity and survival in locally advanced laryngeal cancer. Head and Neck, 2018, 40, 2060-2069.	0.9	20
231	Water bolus for electron irradiation of the ear canal. International Journal of Radiation Oncology Biology Physics, 1995, 33, 479-483.	0.4	19
232	A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma. Radiotherapy and Oncology, 2002, 63, 187-193.	0.3	19
233	Mucositis: current management and investigations. Seminars in Radiation Oncology, 2003, 13, 267-273.	1.0	19
234	Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. Radiotherapy and Oncology, 2018, 126, 75-80.	0.3	19

#	Article	IF	Citations
235	Radiographic retropharyngeal lymph node involvement in HPVâ€associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. Cancer, 2019, 125, 1536-1546.	2.0	19
236	Postoperative radiation of free jejunal autografts in patients with advanced cancer of the head and neck. Cancer, 1995, 75, 2356-2360.	2.0	18
237	Management of Radiation-Induced Severe Anophthalmic Socket Contracture in Patients With Uveal Melanoma. Ophthalmic Plastic and Reconstructive Surgery, 2012, 28, 208-212.	0.4	18
238	Nomogram for Predicting Symptom Severity during Radiation Therapy for Head and Neck Cancer. Otolaryngology - Head and Neck Surgery, 2014, 151, 619-626.	1.1	18
239	Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head and Neck, 2017, 39, 1609-1620.	0.9	18
240	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. Clinical and Translational Radiation Oncology, 2017, 7, 28-35.	0.9	18
241	Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensityâ€modulated radiation therapy. Cancer, 2018, 124, 1415-1427.	2.0	18
242	Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1029-1035.	0.4	18
243	Lymphopenia during radiotherapy in patients with oropharyngeal cancer. Radiotherapy and Oncology, 2020, 145, 95-100.	0.3	18
244	Clinical Implication of Diagnostic and Histopathologic Discrepancies in Sinonasal Malignancies. Laryngoscope, 2021, 131, E1468-E1475.	1.1	18
245	Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia. Radiotherapy and Oncology, 2021, 160, 32-39.	0.3	18
246	Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study. International Journal of Radiation Oncology Biology Physics, 2022, 113, 426-436.	0.4	18
247	Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. International Journal of Radiation Oncology Biology Physics, 1995, 31, 807-811.	0.4	17
248	Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: Phase I study. Oral Oncology, 2006, 42, 946-953.	0.8	17
249	Longitudinal oncology registry of head and neck carcinoma (LORHANÂ®): initial supportive care findings. Supportive Care in Cancer, 2009, 17, 1393-401.	1.0	17
250	The Never-Ending Story: Finding a Role for Neoadjuvant Chemotherapy in the Management of Head and Neck Cancer. Journal of Clinical Oncology, 2014, 32, 2685-2686.	0.8	17
251	Radiation therapy (with or without neck surgery) for phenotypic human papillomavirusâ€“associated oropharyngeal cancer. Cancer, 2016, 122, 1702-1707.	2.0	17
252	Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. International Journal of Cancer, 2016, 138, 1290-1297.	2.3	17

#	Article	IF	Citations
253	Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. British Journal of Cancer, 2021, 124, 628-633.	2.9	17
254	ORGAN PRESERVATION FOR CARCINOMA OF THE LARYNX AND HYPOPHARYNX. Hematology/Oncology Clinics of North America, 2001, 15, 243-260.	0.9	16
255	The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 523-531.	0.4	16
256	Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. Head and Neck, 2017, 39, 633-638.	0.9	16
257	Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating. Radiotherapy and Oncology, 2019, 133, 35-42.	0.3	16
258	Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma. International Journal of Particle Therapy, 2016, 2, 533-543.	0.9	16
259	Salivary flow rates measured during radiation therapy in head and neck cancer patients: A pilot study assessing salivary sediment formation. Journal of Prosthetic Dentistry, 2008, 100, 142-146.	1.1	15
260	Outcomes of patients with tonsillar carcinoma treated with postâ€tonsillectomy radiation therapy. Head and Neck, 2010, 32, 473-480.	0.9	15
261	Looking Beyond the Numbers: Highlighting the Challenges of Population-Based Studies in Cancer Research. Journal of Clinical Oncology, 2016, 34, 2317-2318.	0.8	15
262	Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. Head and Neck, 2017, 39, 2079-2087.	0.9	15
263	Postoperative local-regional radiation therapy in the treatment of parathyroid carcinoma: The MD Anderson experience of 35 years. Practical Radiation Oncology, 2017, 7, e463-e470.	1.1	15
264	Decreased gastrostomy tube incidence and weight loss after transoral robotic surgery for lowâ€toâ€intermediateâ€risk oropharyngeal squamous cell carcinoma. Head and Neck, 2018, 40, 2507-2513.	0.9	15
265	Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, singleâ€institution, modern cohort study. Head and Neck, 2021, 43, 3331-3344.	0.9	15
266	Outcomes for hypopharyngeal carcinoma treated with organâ€preservation therapy. Head and Neck, 2016, 38, E2091-9.	0.9	14
267	Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching â€˜liquid biopsyâ€™ and quantitative tumor modeling. BMC Cancer, 2018, 18, 903.	1.1	14
268	A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findings from a randomized trial. Radiotherapy and Oncology, 2019, 130, 46-55.	0.3	14
269	<scp>Highly conformal</scp> reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. Head and Neck, 2020, 42, 3326-3335.	0.9	14
270	Determinants of patientâ€reported xerostomia among longâ€term oropharyngeal cancer survivors. Cancer, 2021, 127, 4470-4480.	2.0	14

#	Article	IF	Citations
271	Total Midface Reconstruction After Radical Tumor Resection. Annals of Plastic Surgery, 1996, 36, 551-557.	0.5	13
272	Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 1: Fluorides. Oral Oncology, 2006, 42, 934-945.	0.8	13
273	CT Findings in Temporal Bone Osteoradionecrosis. Journal of Computer Assisted Tomography, 2014, 38, 662-666.	0.5	13
274	Estimation of daily interfractional larynx residual setup error after isocentric alignment for head and neck radiotherapy: quality assurance implications for target volume and organsâ€¤atâ€¤risk margination using daily CT onâ€¤rails imaging. Journal of Applied Clinical Medical Physics, 2015, 16, 159-169.	0.8	13
275	Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: Quantitative image analysis of post-radiotherapy response. Oral Oncology, 2015, 51, 195-201.	0.8	13
276	Radiationâ€¤associated malignancies of the ear canal and temporal bone. Laryngoscope, 2015, 125, 1198-1204.	1.1	12
277	Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Supportive Care in Cancer, 2020, 28, 261-269.	1.0	12
278	Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 185-193.	0.4	12
279	Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. Oral Oncology, 2021, 113, 105125.	0.8	12
280	Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy. Radiotherapy and Oncology, 2021, 159, 21-27.	0.3	12
281	To TORS or Not to TORS: But Is That the Question?. JAMA Otolaryngology, 2010, 136, 1085.	1.5	11
282	Anisotropic Margin Expansions in 6 Anatomic Directions for Oropharyngeal Image Guided Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, 596-601.	0.4	11
283	Reply to B. O'Sullivan et al. Journal of Clinical Oncology, 2015, 33, 1708-1709.	0.8	11
284	Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirusâ€“associated oropharyngeal cancer. Head and Neck, 2016, 38, E1554-61.	0.9	11
285	The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors. Clinical and Translational Radiation Oncology, 2020, 24, 71-78.	0.9	11
286	Outcomes after radiation therapy for <scp>T2N0</scp>/stage <scp>II</scp> glottic squamous cell carcinoma. Head and Neck, 2020, 42, 2791-2800.	0.9	11
287	Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. Radiotherapy and Oncology, 2020, 148, 133-139.	0.3	11
288	Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. Current Treatment Options in Oncology, 2021, 22, 54.	1.3	11

#	Article	IF	Citations
289	Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. International Journal of Particle Therapy, 2021, 8, 319-327.	0.9	11
290	Knowledgeâ€based planning for the radiation therapy treatment plan quality assurance for patients with head and neck cancer. Journal of Applied Clinical Medical Physics, 2022, 23, e13614.	0.8	11
291	Results of a changing treatment philosophy for children with stage I Hodgkin's disease: A 35-year experience. Medical and Pediatric Oncology, 1991, 19, 214-220.	1.0	10
292	Is There Still a Role for Induction Chemotherapy for Head and Neck Cancer?. Journal of Clinical Oncology, 2005, 23, 1059-1060.	0.8	10
293	Head and neck radiation and mucositis. Current Opinion in Supportive and Palliative Care, 2007, 1, 30-34.	0.5	10
294	Orbital carcinomas treated with adjuvant intensityâ€modulated radiation therapy. Head and Neck, 2016, 38, E580-7.	0.9	10
295	Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers. Radiotherapy and Oncology, 2020, 151, 119-125.	0.3	10
296	Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases. Physics and Imaging in Radiation Oncology, 2020, 14, 1-5.	1.2	9
297	Risk and Clinical Risk Factors Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Squamous Cell Carcinoma Survivors. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 469.	1.2	9
298	Psychosocial and Economic Impact of Cancer. Dental Clinics of North America, 2008, 52, 231-252.	0.8	8
299	Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. Radiation Oncology, 2017, 12, 129.	1.2	8
300	Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precision Oncology, 2018, 2, 1-11.	1.5	8
301	The role of salvage surgery with interstitial brachytherapy for the Management of Regionally Recurrent Head and Neck Cancers. Cancers of the Head & Neck, 2019, 4, 4.	6.2	8
302	Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. Cancer, 2020, 126, 749-756.	2.0	8
303	Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. Advances in Radiation Oncology, 2020, 5, 929-935.	0.6	8
304	Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. International Journal of Particle Therapy, 2021, 8, 108-118.	0.9	8
305	Concurrent epithelioid malignant peripheral nerve sheath tumor and papillary thyroid carcinoma in the treated field of Hodgkin's disease. Head and Neck, 2008, 30, 675-679.	0.9	7
306	CT-based volumetric tumor growth velocity: A novel imaging prognostic indicator in oropharyngeal cancer patients receiving radiotherapy. Oral Oncology, 2016, 63, 16-22.	0.8	7

#	Article	IF	Citations
307	Fabrication of an unconventional bolus-type stent for aÂcombined intraoral/extraoral defect treated with protonÂradiation therapy. Journal of Prosthetic Dentistry, 2017, 117, 563-565.	1.1	7
308	Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. Journal of Neurological Surgery, Part B: Skull Base, 2020, 81, 638-644.	0.4	7
309	A Dosimetric Comparison of Oral Cavity Sparing in the Unilateral Treatment of Early Stage Tonsil Cancer: IMRT, IMPT, and Tongue-Deviating Oral Stents. Advances in Radiation Oncology, 2020, 5, 1359-1363.	0.6	7
310	Longitudinal characterization of the tumoral microbiome during radiotherapy in HPV-associated oropharynx cancer. Clinical and Translational Radiation Oncology, 2021, 26, 98-103.	0.9	7
311	The impact of induction and/or concurrent chemoradiotherapy on acute and late patientâ€reported symptoms in oropharyngeal cancer: Application of a mixedâ€model analysis of a prospective observational cohort registry. Cancer, 2021, 127, 2453-2464.	2.0	7
312	Where are the at-risk cervical nodes?. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1-2.	0.4	6
313	Erratum to â€œClinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: Phase I studyâ€. Oral Oncology, 2007, 43, 98-105.	0.8	6
314	Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncology, 2018, 79, 1-8.	0.8	6
315	Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. Journal of Neurosurgery, 2019, 130, 812-821.	0.9	6
316	A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods. Oral Oncology, 2020, 106, 104665.	0.8	6
317	18FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer. Clinical and Translational Radiation Oncology, 2021, 29, 93-101.	0.9	6
318	Unilateral Radiotherapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papilloma Virus (HPV), Positron-emission Tomography (PET) and Intensity-modulated Radiation Therapy (IMRT). International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	6
319	Impact of changes to the American Joint Committee on Cancer T classification on outcome prediction in patients with oropharyngeal cancer. Cancer, 2006, 106, 1950-1957.	2.0	5
320	Clinical characteristics of patients with multiple potentially human papillomavirus-related malignancies. Head and Neck, 2014, 36, 819-825.	0.9	5
321	Predicting oropharyngeal tumor volume throughout the course of radiation therapy from pretreatment computed tomography data using general linear models. Medical Physics, 2014, 41, 051705.	1.6	5
322	Larynx and Hypopharynx Cancer. , 2016, , 649-672.e4.		5
323	Cognitive function and patientâ€reported memory problems after radiotherapy for cancers at the skull base: A crossâ€sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventoryâ€Head and Neck Module. Head and Neck, 2017, 39, 2048-2056.	0.9	5
324	Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?. Clinical and Translational Radiation Oncology, 2020, 22, 98-105.	0.9	5

#	Article	IF	Citations
325	The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/â˜ systemic therapy in locally advanced head and neck cancer. Journal of Geriatric Oncology, 2021, 12, 937-944.	0.5	5
326	Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 615.	1.2	5
327	Two-field versus three-field irradiation technique in the postoperative treatment of head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 469-476.	0.4	4
328	Development and validation of a contouring guideline for the taste bud bearing tongue mucosa. Radiotherapy and Oncology, 2021, 157, 63-69.	0.3	4
329	Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes. International Journal of Particle Therapy, 2021, 8, 261-272.	0.9	4
330	Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. International Journal of Particle Therapy, 2021, 8, 234-247.	0.9	4
331	Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer. International Journal of Particle Therapy, 2021, 8, 374-382.	0.9	4
332	Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHNSCC).. Journal of Clinical Oncology, 2015, 33, 6001-6001.	0.8	4
333	ECOG-ACRIN 1308: Commentary on a Negative Phase II Trial. Journal of Clinical Oncology, 2017, 35, 1969-1970.	0.8	3
334	Not All 30-Gy Regimens Are Equal. Journal of Clinical Oncology, 2019, 37, 3558-3559.	0.8	3
335	A prospective evaluation of healthâ€related quality of life after skull base reâ€irradiation. Head and Neck, 2020, 42, 485-497.	0.9	3
336	Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. Head and Neck, 2020, 42, 2137-2144.	0.9	3
337	SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. Practical Radiation Oncology, 2020, 10, 363-371.	1.1	3
338	Defining the doseâ€volume criteria for laryngeal sparing in locally advanced oropharyngeal cancer utilizing splitâ€field IMRT, wholeâ€field IMRT and VMAT. Journal of Applied Clinical Medical Physics, 2021, 22, 37-44.	0.8	3
339	Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. Clinical and Translational Radiation Oncology, 2022, 32, 35-40.	0.9	3
340	Association of hearing loss and tinnitus symptoms with <scp>healthâ€related</scp> quality of life among <scp>longâ€term</scp> oropharyngeal cancer survivors. Cancer Medicine, 0, , .	1.3	3
341	Forecasting longitudinal changes in oropharyngeal tumor morphology throughout the course of head and neck radiation therapy. Medical Physics, 2014, 41, 081708.	1.6	2
342	In Regard to Routman etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1295-1296.	0.4	2

#	Article	IF	Citations
343	Optimizing laryngeal sparing with intensity modulated radiotherapy or volumetric modulated arc therapy for unilateral tonsil cancer. Physics and Imaging in Radiation Oncology, 2019, 10, 29-34.	1.2	2
344	Postoperative Radiation Therapy for Metastatic Cervical Adenopathy. Seminars in Radiation Oncology, 2019, 29, 144-149.	1.0	2
345	Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer, 2021, 127, 1228-1237.	2.0	2
346	Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. International Journal of Particle Therapy, 2021, 8, 213-222.	0.9	2
347	Larynx and Hypopharynx Cancer. , 2012, , 639-663.		2
348	Risk factors associated with patientâ€reported fatigue among longâ€term oropharyngeal carcinoma survivors. Head and Neck, 2022, 44, 952-963.	0.9	2
349	Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors. Scientific Reports, 2022, 12, 6662.	1.6	2
350	41 Concomitant boost radiotherapy for squamous carcinoma of the tonsillar fossa. International Journal of Radiation Oncology Biology Physics, 1995, 32, 161.	0.4	1
351	In Regard to Kjems etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 96, 240.	0.4	1
352	Reply to radiotherapy for human papillomavirusâ€positive oropharyngeal cancers in the National Cancer Data Base. Cancer, 2016, 122, 3411-3412.	2.0	1
353	Surgical Treatment for T4 Oropharyngeal Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 96.	1.2	1
354	Factors associated with complex oral treatment device usage in patients with head and neck cancer. Clinical and Translational Radiation Oncology, 2021, 30, 78-83.	0.9	1
355	Xerostomia. , 2007, , 185-199.		1
356	Carcinoma of the Paranasal Sinuses and Olfactory Neuroblastoma. , 2005, , 371-384.		1
357	The influence of radiation dose on taste impairment in a prospective observational study cohort of oropharyngeal cancer patients. Acta OncolÃ³gica, 2022, 61, 146-152.	0.8	1
358	Phase II study of polymyxin B, tobramycin, and clotrimazole to prevent oral irradiation mucositis. Radiation Oncology Investigations, 1996, 4, 23-26.	1.3	0
359	New equations for matching a low neck field to oblique upper neck fields with collimator rotation in a 3-field monoisocentric setup for head-and-neck cancers. Medical Dosimetry, 2004, 29, 86-91.	0.4	0
360	Oral Complications of Cancer Therapy. , 2006, , 1349-1362.		0

#	Article	IF	Citations
361	Response to Letter by Dr. Ibott et al.. International Journal of Radiation Oncology Biology Physics, 2010, 76, 639.	0.4	0
362	Comparing surgery and radiation in the treatment of oropharyngeal cancer. Head and Neck, 2012, 34, 1198-1199.	0.9	0
363	Letter to the Editor regarding transoral laser microsurgery followed by radiotherapy in advanced oropharyngeal cancer. Head and Neck, 2014, 36, 1674-1675.	0.9	0
364	Reply to D. Adkins et al. Journal of Clinical Oncology, 2015, 33, 1224-1225.	0.8	0
365	In Regard to Arthurs etÂal. International Journal of Radiation Oncology Biology Physics, 2017, 97, 440.	0.4	0
366	Transoral Robotic Surgery-Assisted Endoscopy. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 1058.	1.2	0
367	In Regard to Sher et al. Practical Radiation Oncology, 2018, 8, 66-67.	1.1	0
368	Regular Olâ€™ Intensity. International Journal of Radiation Oncology Biology Physics, 2020, 107, 615.	0.4	0
369	SU-E-J-138: The Effect of Shoulder Variation on IMRT and SmartArc Plans for Head and Neck Cancer. Medical Physics, 2011, 38, 3474-3474.	1.6	0
370	Postoperative Intensity-Modulated Radiation Therapy for Head and Neck Cancers: A Case-Based Review. , 2015, , 193-213.		0
371	Primary Mucosal Melanomas of the Head and Neck. , 2016, , 641-656.		0
372	Transoral Surgery With Neck Dissection Is an Excellent Treatment for the Appropriately Selected Patient With Early-Stage Oropharyngeal Cancer. Journal of Clinical Oncology, 2022, 40, 1132-1133.	0.8	0
373	Feasibility of Mobile and Sensor Technology for Remote Monitoring in Cancer Care and Prevention.. AMIA ... Annual Symposium proceedings, 2021, 2021, 979-988.	0.2	0